Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and carboplatin added to standard neoadjuvant chemotherapy for early-stage triple-negative breast cancer
2013-002377-21Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of veliparib and carboplatin in triple-negative breast cancer (TNBC) and breast cancer (3 arms), sponsored by AbbVie Inc. Primary endpoint: pathological complete response. Started Apr 2014; status: completed.
02
Drugs
veliparibcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2013-002377-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002377-21.